Short answer
Erasca, Inc. (ERAS) filed its Q3 2026 10-Q quarterly report on Nov 12, 2026 for the quarter ended Sep 30, 2026.
Q3 2026 key financials · XBRL
- Net income
- −$51M
- −67.7% YoY · −16.5% QoQ
- EPS (diluted)
- −$0.13
- −18.2% YoY · +7.1% QoQ
Source: XBRL data from the Erasca, Inc. (ERAS) Q3 2026 10-Q on SEC EDGAR. USD.
Erasca, Inc. Q3 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $0, unchanged YoY, reflecting no approved products or product sales
- Net loss $51.3M vs $30.6M YoY, operating loss $59.5M vs $34.5M
- ERAS-0015 strongest program, 57% uORR at 32 mg QD in 2L+ KRAS G12X PDAC
- Cash, equivalents and marketable securities $947.8M, supported by $593.5M July offering
- Operating cash outflow $87.4M vs $73.7M YoY, with $712.7M investing outflow and $845.2M financing inflow
Risk Factors
- New IP infringement risk triggered by RevMed’s April 24, 2026 letter targeting ERAS-0015 and alleging patent infringement and trade-secret misappropriation
- New securities litigation risk triggered by June 10, 2026 class action and August 2026 derivative complaint
- Regulatory and compliance risk: RevMed alleges improper comparative preclinical disclosures involving ERAS-0015 and RMC-6236
- Operational risk: potential injunctions could delay or prevent ERAS-0015 development and commercialization
- Financial risk: litigation could produce substantial legal fees, monetary damages, settlements, fines, or penalties
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Erasca, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.